Mendus

.Hero-module--bg-image--629a6.gbi-1276703326-fNXGPieGPufWY5qSmg7du4:before { opacity: 1; background-image: url('/static/64ff3c5dc09358fb1f6e6ee5f4a8dcf4/e65ba/Mendus_woman-with-surfboard_darker-min-compress.jpg'); }

Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.

<picture><source type="image/webp" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/dbb21/disarming-cancer-threat.webp 151w,/static/f6777646b01027295d9a7ee75dea7c96/8cdf4/disarming-cancer-threat.webp 302w,/static/f6777646b01027295d9a7ee75dea7c96/39272/disarming-cancer-threat.webp 603w" sizes="(min-width: 603px) 603px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 603px) 603px, 100vw" decoding="async" loading="lazy" src="/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/bedb7/disarming-cancer-threat.jpg 151w,/static/f6777646b01027295d9a7ee75dea7c96/8f82e/disarming-cancer-threat.jpg 302w,/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg 603w" alt="&lt;p&gt;Middle aged man running in a field of grass, surrounded by mountains.&lt;/p&gt;
"/></picture>
Gaining the 
upper handToday, tumor recurrence causes the vast majority of cancer-related deaths. We want to change this by designing new therapeutic options that tip the balance in favor of the immune system.
What we do

<picture><source type="image/webp" srcSet="/static/aafedabe406814250bbca33ccd38dca0/5b094/ways-to-make-dif.webp 225w,/static/aafedabe406814250bbca33ccd38dca0/ecbb3/ways-to-make-dif.webp 450w,/static/aafedabe406814250bbca33ccd38dca0/10d3d/ways-to-make-dif.webp 900w" sizes="(min-width: 900px) 900px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 900px) 900px, 100vw" decoding="async" loading="lazy" src="/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg" srcSet="/static/aafedabe406814250bbca33ccd38dca0/51892/ways-to-make-dif.jpg 225w,/static/aafedabe406814250bbca33ccd38dca0/ea40c/ways-to-make-dif.jpg 450w,/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg 900w" alt=""/></picture>
New ways to make a differenceWe dare to shine the light of science down new and unexplored paths to improve the course of cancer treatment.
About us

Latest newsAll news
15 March 2023Latest
Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023
Durable Vaccine-Induced T-Cell Responses Observed in the Majority of Vididencel-Treated Patients...
Learn more
7 March 2023
Mendus secures second shareholder loan from Van Herk Investments and reduces the number of outstanding convertible bonds with Negma Group
Mendus AB today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk Investments...
Learn more
6 March 2023
Mendus to participate in upcoming conferences in March 2023
Mendus AB (“Mendus” publ; IMMU.ST), today announced its participation in the following upcoming investor and industry conferences...
Learn more
28 February 2023
Mendus AB: Change in number of shares and votes in Mendus AB (publ)
During February, the number of shares and votes in Mendus AB (publ) has changed as a result of 773,017 new shares being issued to Negma Group upon conversion of convertible bonds.  The issue of shares...
Learn more
17 February 2023
Mendus AB (publ) announces Q4 and year-end results 2022
“We are very happy with the progress we have made on all fronts in 2022 and the continued commitment of our entire team to develop impactful new cancer therapies. For 2023, we have taken necessary steps to focus on our most value-generating projects...
Learn more
31 January 2023
DCP-001 becomes vididencel
The INN name “vididencel” was selected by the World Health Organization’s International Nonproprietary Names Expert Committee and we will increasingly use it in all our materials.
Learn more
5 January 2023
Mendus AB: Mendus announces request of first tranche of convertible loan from Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has requested the first tranche of a...
Learn more

For investors
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors
<picture><source type="image/webp" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/7bc26/124.webp 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/5e603/124.webp 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/af8c4/124.webp 1656w" sizes="(min-width: 1656px) 1656px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1656px) 1656px, 100vw" decoding="async" loading="lazy" src="/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/1d336/124.jpg 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/8753d/124.jpg 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg 1656w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Latest presentation20 March 2023Corporate Presentation - Mar. 2023
13 December 2022Replay of ASH 2022 Webcast
30 November 2022Replay of Mendus' KOL Event
Financial calendar17 February 2023Publication of Year-end Report 2022
17 April 2023Publication of Annual Report 2022
12 May 2023Annual General Meeting
12 May 2023Publication of Q1 Report
29 August 2023Publication of Q2 Report
9 November 2023Publication of Q3 Report
14 February 2024Publication of Year-end Report 2023

EventsAll events
14 April 2023
Upcoming
AACR Annual Meeting 2023Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting. Members of Mendus' leadership team and Business Development team will participate.
Learn more
April 2023Upcoming
Innovation for Health 2023
CEO Erik Manting will participate.
Learn more
March 2023Upcoming
8th Annual Innate Killer Summit
Erik Manting, CEO of Mendus, will give a presentation and update on Mendus’ novel method for the expansion of memory NK cells.
Learn more
March 2023Previous
BIO-Europe Spring 2023
Members of Mendus’ leadership team will participate.
Learn more

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--1792894973-nJxb3nPKGCnaXtGH9HXDqp:before { opacity: 1; background-image: url('/static/db5cac225ec6b40b3e48015942da980e/d3468/home-section-fullwidth.jpg'); }

A life-changing careerAt Mendus, we share a strong commitment to improve the lives of people with cancer. And we do it as a team who values honesty and togetherness. Join us and help change cancer treatment at its core.
Careers

Changing the course of cancer treatment

Gaining the upper hand

New ways to make a difference

Latest news

Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023

Mendus secures second shareholder loan from Van Herk Investments and reduces the number of outstanding convertible bonds with Negma Group

Mendus to participate in upcoming conferences in March 2023

Mendus AB: Change in number of shares and votes in Mendus AB (publ)

Mendus AB (publ) announces Q4 and year-end results 2022

DCP-001 becomes vididencel

Mendus AB: Mendus announces request of first tranche of convertible loan from Negma Group

For investors

Invest in future cancer care

Latest presentation

Financial calendar

Events

AACR Annual Meeting 2023

Innovation for Health 2023

8th Annual Innate Killer Summit

BIO-Europe Spring 2023

A life-changing career

Keep up to date

Gaining the
upper hand